Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
Inflammatory reactions contribute to the pathogenesis of cardiovascular conditions such as atherosclerosis and ischemic damage in acute myocardial infarction (AMI). Among the mediators involved in inflammation are secretory phospholipase A2 group II (sPLA2-II) enzymes. Though some cells constitutively express sPLA2-II, the synthesis by cells such as hepatocytes is typical for an acute-phase reactant. Recent literature suggests multiple roles for sPLA2-II in cardiovascular disease. In this review we discuss the role of sPLA2-II in various in vivo and in vitro models of atherosclerosis or AMI, including the therapeutic perspective of sPLA2-II inhibitors. It was concluded that sPLA2-II appears to be an important inflammatory mediator of cardiovascular disease.
Niessen
Hans W M
HW
ICaR-VU, VU Medical Center, Amsterdam, The Netherlands. jwm.niessen@vumc.nl
Krijnen
Paul A J
PA
Visser
Cees A
CA
Meijer
Chris J L M
CJ
Erik Hack
C
C
D001161:Arteriosclerosis / Q000201:enzymology* / Q000276:immunology; D042783:Endothelial Cells / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D054501:Group II Phospholipases A2; D006801:Humans; D008074:Lipoproteins / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D017202:Myocardial Ischemia / Q000201:enzymology* / Q000276:immunology; D032383:Myocytes, Cardiac / Q000201:enzymology*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010741:Phospholipases A / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D054467:Phospholipases A2
D004791:Enzyme Inhibitors; D008074:Lipoproteins; D016376:Oligonucleotides, Antisense; D010741:Phospholipases A; D054501:Group II Phospholipases A2; D054467:Phospholipases A2